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Enterotoxigenic  Escherichia  coli (ETEC)  is  one  of the  most  common  bacterial  causes  of diarrhea-associated
morbidity  and  mortality,  particularly  among  infants  and  young  children  in developing  countries.  Still,  the
true impact  on  child  and  traveler  health  is  likely  underestimated.  There  are  currently  no  licensed  vaccines
for ETEC,  but  studies  indicate  high  public  health  impact,  cost-effectiveness,  and  feasibility  of  immune  pro-
tection  through  vaccination.  ETEC  vaccine  development  remains  a World  Health  Organization  priority.
Traditionally,  ETEC  vaccine  development  efforts  have  focused  on  inducing  antitoxin  and  anticolonization
antigen  immunity,  as  studies  indicate  that antibodies  against  both  antigen  types  can  contribute  to pro-
tection  and thus  have  potential  for vaccines.  Leading  cellular  vaccine  candidates  are  ETVAX (a  mixture
of  four  inactivated  strains)  and  ACE527  (a  mixture  of  three  live  attenuated  strains),  both  of  which  have
been  found  to  be safe and  immunogenic  in Phase  1/2 trials.  ETVAX  is  the  furthest  along  in development
with  descending-age  studies  already  underway  in  Bangladesh.  Other  ETEC  vaccine  candidates  based  on
protein  subunits,  toxoids  (both  LT  and  ST),  or novel,  more  broadly  conserved  ETEC  antigens  are  also  under
development.  Of  these,  a protein  adhesin-based  subunit  approach  is  the  most  advanced.  Impact  and  eco-
nomic  models  suggest  favorable  vaccine  cost-effectiveness,  which  may  help  expand  market  interest  in
ETEC vaccines.  Combination  vaccine  formulations  may  help  improve  the  economic  case  for development
and  use,  and better  point-of-care  diagnostics  will  help  to  raise  awareness  of  the  true  health  burden  of
ETEC  and  highlight  the  potential  public  health  beneﬁt  of ETEC  vaccine  introduction.  Better  diagnostics  and
vaccine  demand  forecasting  will  also  improve  vaccine  development  ﬁnancing  and  support  accelerated
uptake  once  a licensed  vaccine  becomes  available.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC. About the disease and pathogen
Enterotoxigenic Escherichia coli (ETEC) remains among the most
ommon bacterial causes of diarrhea-associated morbidity and
ortality [1–4]. ETEC is often the ﬁrst bacterial illness that chil-
ren experience in endemic areas, with infants and young children
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experiencing two  to ﬁve diarrhea episodes due to ETEC during their
ﬁrst three years of life. Recent studies in sub-Saharan Africa and
South Asia conducted under the Global Enteric Multicenter Study
(GEMS) reafﬁrmed the continuing importance of ETEC as one of
the top four causes of moderate-to-severe diarrhea (MSD) among
children less than ﬁve years of age seeking care for their illness
at health centers in both regions [3]. Similarly, in a prospective
community-based diarrhea study in South America, Africa, and
Asia, the Interactions of Malnutrition and Enteric Infections: Conse-
quences for Child Health and Development (MAL-ED) project found
ETEC to be an important cause of diarrheal illness in the second year
of life in these regions, where it was  frequently associated with
more severe acute illness and persistent diarrhea [4]. GEMS data
also indicate that children with MSD  are in a subgroup that is at
higher risk of dying or being stunted, and that cases infected with
heat-stable (ST) toxin-positive ETEC strains, which includes ETEC
strains expressing ST toxin alone or in combination with heat-labile
(LT) toxin, were more likely to have these poor health outcomes;
although it remains to be determined if these relationships in GEMS
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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re causal [3]. In MAL-ED, diarrhea episodes associated with gut
nﬂammatory markers or changes in permeability were associated
ith stunting. Illness associated with diarrheagenic E. coli, includ-
ng ETEC, contributed to this linear growth faltering [5]. Although
oth studies highlight the continuing importance of ETEC as a sig-
iﬁcant cause of diarrhea-associated morbidity and mortality in
eveloping countries, it is likely that these estimates, based on more
raditional culture-based detection methods, may  underestimate
TEC’s actual health impact. A recent reanalysis of GEMS samples
sing more molecular-based, quantitative polymerase chain reac-
ion (qPCR) technology [6] suggests that this approach may  give a
etter picture of the true burden of ETEC-associated MSD  as well
s other bacterial pathogen-related MSD  and their relative roles in
nfant mortality and stunting.
In 2010, the Global Burden of Disease (GBD) study estimated
nnual mortality from illness due to ETEC at 157,000 deaths – 9%
f all deaths attributed to diarrhea and approximately 1% of all
eaths in children 28 days to 5 years of age [7]. The World Health
rganization (WHO) Child Health Epidemiology Reference Group
CHERG), which uses a different methodology, estimated 42,000
95% CI, 20,000–76,000) ETEC-associated deaths of children under
ve years of age in 2013 [8]. In older age groups, a meta-analysis of
ospitalization and stool culture data projected that ETEC may  con-
ribute to an additional 89,000 deaths per year among age groups
lder than ﬁve years in Africa and South Asia [9]. In addition to
ortality estimates, morbidity estimates in 2010 projected ETEC
isability-Adjusted Life Years (DALYs) at 8.5 million (10% of all diar-
hea DALYs) and Years Lived with Disability (YLDs) due to ETEC at
 million (13% of all diarrhea YLDs) [10,11]. The meta-analysis also
ound that, in 2010, ETEC was signiﬁcantly more common in age
roups older than 5 years than cholera and typhoid combined, with
4 million cases of ETEC versus 9 million typhoid and cholera cases
6 and 3 million, respectively) [9]. Across all diseases, school-age
hildren were at the highest risk for illness [9]. Moreover, another
eta-analysis describing the etiology of diarrhea among individ-
als in older age groups suggests that ETEC may  be associated with
0–14% of hospitalized cases and 6% of all diarrheal illnesses in
utpatient and community settings.
ETEC is also the most frequent bacterial cause of diarrhea among
ravelers to Africa, Asia, and Latin America, including military
ersonnel deployed to these areas. ETEC is estimated to cause
pproximately 10 million episodes of travelers’ diarrhea each year
1,2]. Recent data also strongly suggest that ETEC infections in
ravelers can increase the risk of subsequent functional bowel dis-
rders. In fact, 10–14% of travelers recovering from ETEC-associated
ravelers’ diarrhea may  go on to develop irritable bowel syndrome
12], further highlighting the importance of ETEC prevention and
he potential beneﬁt of effective ETEC vaccines [2,12,13].
In the classical paradigm for ETEC pathogenesis, these bacteria
rst colonize the small intestine, where they employ plasmid-
ncoded ﬁmbrial colonization factor (CF) or coli surface (CS)
ntigens to bind to enterocytes in the upper small intestine [1,2].
ere, they produce ST and/or LT enterotoxins, and their close
ssociation with enterocytes via their CF/CS antigens promotes
ransfer of ETEC enterotoxins that stimulate the release of ﬂuid
nd electrolytes from the intestinal epithelium, resulting in watery
iarrheal illness [1,2]. These plasmid-encoded antigens are consid-
red to be key virulence factors and have therefore been intensively
tudied over the last three decades. Recent data has supported
n immune modulatory role for ST that may  reduce the ability
f infected hosts to mount effective innate and adaptive immune
esponses to the infecting ETEC organism [14]. Whether this pro-
osed immunomodulatory role for ST toxin contributes to the
oorer health outcomes associated with the ST-ETEC infections in
EMS and MAL-ED remains to be determined, but future investiga-
ion of ST toxin’s additional role(s) in ETEC pathogenesis warrants 34 (2016) 2880–2886 2881
more in-depth study. In a similar vein, as indicated above, the LT
toxin is a well-accepted virulence factor for those ETEC strains that
produce it [1,2]. However, a less-appreciated role for this toxin
in ETEC pathogenesis is its contribution as an accessory coloniza-
tion factor and also as a potential co-factor in promoting intestinal
colonization by other enteric pathogens, like Salmonella enterica
[15]. Promotion of intestinal colonization by Salmonella has only
been observed in pigs to date, but given the potential impact of
this observation, it warrants further study in humans since it may
contribute to some of the more long term poor health outcomes
associated with ETEC infections in both the GEMS and MAL-ED
studies, while highlighting the importance of including a toxoid
component in future ETEC vaccine formulations [16,17]. Prior ﬁeld
studies of cholera and ETEC vaccines have suggested that formu-
lations containing LT or the cross-reactive CTB toxoid not only
can give protection against LT-producing ETEC strains but also
intriguing short-term protection against Salmonella and possibly
Campylobacter [18–20].
While more than 25 unique CF/CS types and putative factors
have been characterized so far, one or more of these known CFs have
been identiﬁed in only about 50% of ETEC clinical isolates. There-
fore, as mentioned previously, standard bacterial culture methods
and supportive laboratory-based secondary assays used in clinical
microbiology laboratories around the world likely underestimate
the true incidence of ETEC [6]. This has stimulated renewed inter-
est in more sensitive and speciﬁc point-of-care diagnostics and in
exploring more novel adhesins and other conserved ETEC proteins
contributing to virulence that may  go undetected using standard
molecular biology and immunological approaches [2,19,21]. The
prominent role played by ST-producing ETEC in GEMS  and MAL-ED
has also triggered renewed efforts to make a safe and immuno-
genic ST toxoid for inclusion in future ETEC vaccine formulations
[21–23].
ETEC is transmitted via the fecal-oral route and is associ-
ated with the consumption of contaminated water or food. Like
most enteric pathogens, multi-drug resistance is becoming more
common [1,2]. Because ETEC-associated MSD is an enterotoxic,
non-invasive disease of the small intestine, rehydration therapy
can be beneﬁcial. However, given growing concerns about the
longer-term health effects of ETEC illness, prevention remains an
important area to address. As indicated above, recent GBD  data
highlight ETEC as an important global contributor to diarrhea-
associated mortality, DALYs, and YLDs [7,8,10,11] and, despite
declining mortality, ETEC-associated morbidity has not changed
signiﬁcantly over the last 20 years. Moreover, based on the appli-
cation of more sensitive detection methods mentioned above,
there is likely a signiﬁcant underestimation of its true impact on
child and traveler health. Based on recent vaccine impact and
cost-effectiveness modeling analyses done by the University of
Florida, Johns Hopkins Bloomberg School of Public Health, and
PATH [19,24,25,26], ETEC episodes are estimated to contribute to
an additional 4 million children with moderate-to-severe stunting,
which, in turn, would contribute to an additional 31,000 deaths
annually from diarrhea and comorbidities like pneumonia, malaria,
and measles.
These analyses found that the potential impact of an ETEC vac-
cine differed by region, with the greatest cost-effectiveness ratio
(CER) and impact seen in Africa (US$32.00 for every DALY averted).
In 90 low- and lower-middle-income countries, including those
eligible for support from Gavi, the Vaccine Alliance, the analyses
found a long-term impact and favorable CER of US$65.00/DALY
averted for ETEC vaccines. The CERs are projected to be even more
favorable when modeling efforts incorporate herd immunity effects
into the analysis. Favorable cost-effectiveness estimates have also
been obtained for the introduction of ETEC vaccine into the travel
medicine community [13,19,25,27,28].
2 accine
2
2
ﬁ
i
s
b
f
[
e
c
a
t
[
l
h
f
t
f
t
d
t
c
c
a
i
u
p
s
e
t
s
f
e
[
2
m
t
c
t
a
f
p
i
g
L
u
a
p
m
S
M
b
c
t
C
i
i882 A.L. Bourgeois et al. / V
. Overview of current efforts
.1. Vaccine feasibility
There are currently no licensed vaccines for ETEC. However,
eld studies and human challenge studies indicate that protective
mmunity to ETEC develops after natural or experimental infection,
uggesting that vaccine-induced ETEC immunity should be feasi-
le. In addition, in ETEC-endemic areas, age-speciﬁc attack rates
or symptomatic ETEC infection decline after three years of age
1,2,19,29], and in human challenge studies, subjects who  recov-
red from ETEC diarrhea were protected against disease when
hallenged a second time with the same strain [30–32]. Finally,
ctive immunization with candidate vaccines has led to protec-
ive immunity in limited challenge studies and ﬁeld efﬁcacy trials
1,2,19,20,31,32].
Although vaccine development is clearly feasible, several chal-
enges remain before success can be achieved. ETEC strains are
ighly diverse antigenically, expressing a multitude of colonization
actor and coli surface antigens, toxins, and other virulence pro-
eins. Consequently, vaccines would have to be multicomponent
ormulations to provide the strain coverage needed to be an effec-
ive public health tool [2,19,35]. They must also be formulated and
elivered in such a way that their costs are reasonable and their
olerability and immunogenicity is assured in the two  primary vac-
ine target populations: infants and young children in developing
ountries (0–5-year age range) and adult travelers to ETEC-endemic
reas [19,28,35]. Effective immunization of young children and
nfants in developing countries has proven difﬁcult because of
nderlying gut enteropathy and other health and nutritional issues,
articularly when oral vaccines are being used [19,35,36]. Con-
equently, more novel routes of parenteral delivery need to be
xplored, as well as mucosal adjuvants that may  help overcome
he detrimental effects of gut enteropathy. In addition, vaccines
hould be formulated in such a way as to facilitate their use in
uture combination vaccine strategies that will likely serve to help
nsure better uptake by both private- and public-sector markets
19,28,35,37–39] in the developed and developing world.
.2. General approaches to vaccine development for low- and
iddle-income markets
Traditionally, ETEC vaccine development efforts have focused on
he induction of antitoxin and anticolonization immunity. Speciﬁ-
ally, studies in animals and human subjects indicate that exposure
o LTs, CFs, and CS antigens contribute to protection against ETEC
nd have potential for use in vaccines [1,2,19]. LT is structurally,
unctionally, and immunologically related to cholera toxin (CT); in
articular, the B subunits of LT and CT are closely related and active
mmunization with vaccines formulated to contain LT or CTB have
iven some degree of protection in the ﬁeld [1,2,19,20,34]. Whereas
T is strongly immunogenic on its own, ST is not immunogenic
nless coupled to a carrier protein. To date, no safe ST toxoid is
vailable for use in humans, but as mentioned above, encouraging
rogress is being made in this important area of vaccine develop-
ent [2,19,22,23]. Renewed efforts to develop a safe and effective
T toxoid have been given further impetus by the recent GEMS and
AL-ED results, which indicate that an effective ETEC vaccine must
e able to provide coverage for strains expressing ST alone or in
ombination with LT [3,4].
When considering CFs as vaccine components, it is important
o remember that some CFs are more prevalent than others – e.g.,
FA/I, CS3, CS5, and CS6 account for 50–80% of all CF-positive clin-
cal ETEC isolates [36–38]. In addition, some CF/CS antigens are
mmunologically related to these more prevalent CFs (i.e., CFA/I 34 (2016) 2880–2886
and CS14) [2,19,21,37], so, depending on the vaccine formulation,
cross-protection may  be possible.
Although CF/CSs may  have potential as vaccine components, it
has been suggested that an LT-like toxoid may  help augment CF/CS
induced protection against LT/ETEC, at least in young, immunologi-
cally naïve children. As alluded to above, inclusion of an LT toxoid in
the vaccine may  help to move potential vaccine strain coverage into
the 70–80% range for both infants and young children in developing
countries and travelers to endemic areas, since it may help provide
coverage for LT-only strains that lack CF/CS antigens [19,20]. Active
and passive immunization studies in human volunteers followed
by experimental challenge with wild-type ETEC strains have also
shown that CF and CS antigens alone or in combination with
LTB can provide protection [1,2,19,33,35,40]. In addition, as men-
tioned earlier, including and LT toxoid component in the vaccine
may  help broaden protection to potentially include other enteric
pathogens in some ﬁeld settings, like Salmonella or Campylobacter
[15,16,18,19].
How these human challenge study results translate into ETEC
vaccine efﬁcacy in the ﬁeld remains to be determined. However,
prior challenge studies with inactivated whole-cell cholera vaccine
(precursor of Dukoral®) were very predictive of ﬁeld efﬁcacy for
this vaccine approach [41], and an LT-based prototype ETEC vac-
cine given by transcutaneous patch reduced the severity of ETEC
illness in a human challenge study [42] and showed protective
efﬁcacy against ETEC strains making LT in the ﬁeld [20]. Conse-
quently, vaccines that show an impact on disease incidence and/or
severity in rigorous human challenge models may at least warrant
further development and ﬁeld testing since they may have a pos-
itive impact on disease. The ﬁeld trial results with the LT-patch
were also signiﬁcant because they showed for the ﬁrst time that
skin immunization could protect against an enteric infection like
LT-ETEC in a ﬁeld setting; thus highlighting the potential impor-
tance of skin immunization as a novel way  to deliver new subunit
enteric vaccines, like those being developed for ETEC and Shigella
[17,19,35]. The LT-patch study also indicated the potential impor-
tance of including other ETEC antigens with LT in order to achieve
broader levels of protective efﬁcacy [17].
Efforts to improve vaccine immunogenicity and coverage
remain ongoing on several fronts. One of the most intriguing recent
developments is a new attenuated form of LT called double-mutant
LT (dmLT), which possesses both antigen and adjuvant proper-
ties. Data from human subjects and animals indicate that oral
and parenteral ETEC vaccine candidates may  beneﬁt from adding
dmLT to these vaccine formulations to help improve and sustain
strong intestinal immune responses [2,19,33,43]. Given dmLT’s
unique antigen and adjuvant properties, its inclusion in ETEC vac-
cine formulations may  potentially facilitate vaccine dose sparing
and improved efﬁcacy [2,19]. Data presented at the July 2015 8th
International Conference on Vaccines for Enteric Diseases held in
Edinburgh, Scotland provided the ﬁrst evidence that inclusion of
dmLT in an attenuated ETEC vaccine formulation can have a positive
impact on its protective efﬁcacy in a human challenge model [33].
An earlier trial of dmLT with the inactivated whole cell ETEC vaccine
candidate ETVAX indicated that the addition of dmLT signiﬁcantly
improved the mucosal immune response to the CS6 component in
this vaccine as well as the toxin-neutralizing antibody response to
LT toxin [43,44]. Descending-age safety and immunogenicity stud-
ies of ETVAX, which are now underway at the icddr,b in Dhaka,
Bangladesh, will evaluate the impact of dmLT on vaccine safety and
may  provide some insight regarding effects on immunogenicity and
dose sparing in this ETEC-endemic area (R. Walker, PATH, personal
communication).
Additionally, the application of new “Omics” technologies has
identiﬁed a number of conserved novel proteins that may also con-
tribute to toxin delivery or colonization and thus may  also have
accine
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accine potential, since they tend to be shared across ETEC patho-
ypes. These antigens include ﬂagellin, EtpA, EatA, EaeH, and YghJ
2,19,21]. The potential inclusion of selected antigens from this
roup in future vaccines may  also help broaden vaccine protection
gainst a wider range of ETEC strains and drive antibody responses
o further interfere with two essential steps in ETEC pathogenesis:
ntestinal colonization and effective LT toxin delivery [21,45].
Since ETEC infections are conﬁned to the mucosal surfaces in
he gut and immune protection is most likely provided by locally
roduced secretory IgA antibodies, it has been assumed that assess-
ent of the relative immunogenicity of vaccine candidates should
ocus on antigen-speciﬁc antibody responses induced at the intesti-
al mucosa or on surrogate antibody measures of intestinally
erived antibody responses, like the ELISPOT or ALS responses.
holera studies suggest that T-cell immunity may  also be important
n protection against Vibrio cholerae [46], which is also a lumi-
al bacterial enteropathogen like ETEC. The extent to which T-cell
mmunity to the ETEC antigen may  contribute to the quality of the
ntestinal antibody response to this pathogen remains to be deter-
ined. However, it is starting to become a greater focus of vaccine
evelopment efforts [47,48].
Finally, once an effective vaccine is developed, public health
fﬁcials will need to consider vaccine schedules and delivery mech-
nisms. While infants, young children, and travelers are potential
argets for ETEC vaccine use, the greatest public health beneﬁt
ould likely be achieved by introducing an effective ETEC vaccine
nto the EPI schedule. With this approach, infants in developing
ountries would gain protection from a primary two- to three-dose
mmunization series before they move into the latter part of their
rst year of life, when age-speciﬁc attack rates for ETEC start to
ncrease sharply [1,2,19,29]. To be an effective public health tool, it
s projected that an ETEC vaccine would have to have 50% or greater
fﬁcacy against moderate-to-severe ETEC diarrhea in infants and
oung children.
. Technical and regulatory assessment
The availability of appropriate ETEC challenge models will be
ritical to clinical assessment of how antibodies against CF/CS,
T and/or ST toxoids, and the novel antigens mentioned above
ay  contribute to protection [2,19,30,32]. The ETEC challenge
odel was ﬁrst established in the early 1970s, and its evolution
nd contributions to our understanding of ETEC pathogenesis and
mmunology, as well as to the evaluation of new treatment and
reventive interventions for ETEC, are the focus of a recent in-
epth systematic review [32]. In more recent work, extension of
he fasting time in volunteers prior to challenge appears to facili-
ate lowering the ETEC dose needed to see illness in the majority
f subjects, thus potentially moving the model closer to doses that
ay  actually be encountered in natural ﬁeld exposure [30]. Three
TEC strains (H10407, E24377A, and B7A) have been given to a sig-
iﬁcant number of subjects under US-FDA IND, and in rechallenge
tudies, infection with H10407 and B7A results in strong immunity
gainst rechallenge with the homologous strain [29,30]. In addi-
ion, antitoxin and CF/CS antibody responses in this model appear
o mirror those seen among individuals infected with ETEC in the
eld.
It remains to be determined, however, whether these three ETEC
hallenge strains can meet all the needs of ongoing ETEC vaccine
evelopment efforts. It is anticipated that additional strains may
eed to be evaluated that are representative of other ETEC patho-
ypes. For example, all three of the strains outlined above produce
oth LT and ST, so there may  be a need to further identify and
evelop challenge strains that express only ST or more newly iden-
iﬁed colonization factors. 34 (2016) 2880–2886 2883
The apparent success in lowering the challenge dose for the
H10407 strain of ETEC suggest that this change in fasting time may
enable the ETEC challenge model to become more analogous to the
cholera model, where doses in the 106 cfu range are generally used
[41]. This modiﬁcation also potentially addresses longstanding con-
cerns regarding the ethical issues of exposing volunteers to higher
doses of ETEC than necessary to achieve reasonable disease attack
rates and that higher doses of ETEC might overwhelm any potential
vaccine effects, leading to the premature abandonment of vaccine
candidates that may  have public health potential [32]. Presently,
it is difﬁcult to judge accurately how signiﬁcant this model change
may  be for the ﬁeld. The observations made with the H10407 strain
need to be extended to other ETEC challenge strains, and more vac-
cine immunization and challenge studies need to be done with this
new model before its value to the vaccine development ﬁeld can
be fully appreciated. However, initial studies with two  vaccine con-
cepts, the live attenuated ACE527 vaccine and the adhesin-based
subunit vaccine prototype, have yielded data suggesting its useful-
ness in the early-stage assessment of vaccine efﬁcacy [33,49].
Another issue is that, despite the clear evidence of protection
against diarrheal illness in subjects following experimental infec-
tion and to some extent in the ﬁeld [16,24], clear and consistent
immune correlates of protection or functional assays predicting
immunity against ETEC infection have yet to be established [1,2,19].
The association between the observed antigen-speciﬁc antibody
responses and reduced risk of illness has not been clear in all stud-
ies, and this variability suggests that the responses may  not have
been measured in the best context. The functional aspects of anti-
bodies against these antigens might be a better or more consistent
marker for protection, and other antigens that currently are not
being measured may  also contribute to protection. As mentioned
above, the synergistic interaction of anti-LT toxin and anti-EtpA to
more effectively block intestinal colonization and toxin delivery
in preclinical mouse studies illustrate the potential value of func-
tional read-outs as indicators of antibody activity, as well as tools
in looking at the interaction of antigen–speciﬁc antibody responses
in helping to mediate more complete protection. Therefore, the
development of better functional assays for assessing ETEC immu-
nity is an important technology gap that needs to be addressed.
For example, high throughput assays are needed to more easily
address toxin-neutralizing antibody responses for both LT and ST,
in addition to better HAI assays for measuring functional serum or
fecal antibody responses to CFs in order to better understand how
a vaccine induces responses that block intestinal adherence and
colonization. Similarly, bactericidal assays, much like the ones cur-
rently in use to measure vibriocidal antibody responses – may  also
be a valuable step forward for ETEC vaccines.
Finally, it should be noted that the ﬁeld has yet to integrate a
signiﬁcant systems biology component into protection studies or
to fully apply “Omics” technologies to further facilitate ETEC vac-
cine antigen discovery and immune proﬁling, which may  be better
predictors of broad protection. These new technologies represent
important new tools that could help further accelerate ETEC vac-
cines toward licensure.
4. Status of vaccine R&D activities
Table 1 provides a summary of the development status of
current ETEC vaccine candidates. As indicated above, most ETEC
vaccine candidates currently under development using cellular or
subunit-based vaccine approaches have focused on the induction
of anti-LT and anti-CF/CS antibodies at mucosal and systemic sites.
The leading cellular vaccine candidates include inactivated and
live attenuated approaches: ETVAX (a mixture of four inactivated
strains) and ACE527 (a mixture of three live attenuated strains)
2884 A.L. Bourgeois et al. / Vaccine 34 (2016) 2880–2886
Table 1
Development status of current ETEC vaccine candidates (POC = proof-of-concept trial).
Candidate name/identiﬁer Developer Stage of development References
Preclinical Phase I Phase II POC Phase III
Inactivated tetravalent whole cell supplemented
with LTB–CTB hybrid toxoid; may  include dmLT
adjuvant (ETVAX)
PATH; SBH X [1,2,19,43,44,48,50]
aroC, omp F, and Omp C-based live attenuated; may
include dmLT adjuvant (ACE527)
PATHa X [1,2,19,33]
ZH9 attenuated typhoid vaccine expressing LT-ST
toxoid (Typhetec)
Prokarium X [19,43]
Second-generation 1208S attenuated Shigella
vaccine expressing CF/CS antigens and LT toxoid
CVD X [19,43]
Anti-adhesin based subunit vaccine NMRC; PATH X [2,19,43,47,49]
Anti-adhesin-toxoid fusion (MEFA) KSU; JHBSPH X [2,19]
dmLT PATH X [1,2,19]
LT–ST fusion/LTB–ST conjugate EntVac
consortium;
GLOBVAC;
STOPENTERICS;
PATHb
X [2,19,23]
Flagellin; EtpA; EatA; EaeH; YghJ Variousb X [2,19,21,35,45]
a PATH is seeking developing-country manufacturing partners that could help further develop this vaccine concept.
b Novel toxoids and antigens are being explored by a number of investigators from: Washington University in St. Louis; University of Maryland; University of Virginia;
University of Bergen; South Dakota State University; Kansas State University; the Sanger Institute; Johns Hopkins Bloomberg School of Public Health; and Antigen Discovery,
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1,2,19]. Both have been aided in their development by PATH
1,2,19] and were found to be safe and immunogenic in Phase 1/2
rials. In addition, both were given with the dmLT adjuvant, which
ay  help improve immunogenicity and protective efﬁcacy even
hen given at lower doses than the vaccine alone.
Of these two, ETVAX is the most advanced – it is a fully formu-
ated, complete vaccine ready for ﬁeld testing. PATH is working in a
anufacturing partnership with Scandinavian BioPharma (SBH) for
urther development and testing of ETVAX. This vaccine approach
uilds on and extends the prior work of Ann-Mari Svennerholm and
an Holmgren from the University of Gothenburg who, along with
BL Vaccines, developed and tested a ﬁrst-generation inactivated
hole cell vaccine through efﬁcacy trials in travelers and Egyptian
nfants and young children. The Phase 3 studies were conducted in
ollaboration with Johns Hopkins University, the U.S. Department
f Defense, the U.S. National Institute of Child Health and Human
evelopment, the U.S. National Institutes of Health, and WHO  [1].
espite showing signiﬁcant protection against the more severe
orms of travelers’ diarrhea [1,2] and reasonably good immuno-
enicity in children in both Egypt and Bangladesh, the vaccine
as not protective in the Egyptian Phase 3 pediatric trial [1,2,19].
fter completion of the Phase 3 trial in Egypt, WHO  reviewed
he data from the Egyptian studies in the context of an interna-
ional meeting held in Montreux, Switzerland in 2003 to review
rogress in ETEC vaccine development and to make recommenda-
ions for future directions in research and development [50]. WHO
ecommended further development and study of the inactivated
hole cell vaccine approach for ETEC, with the following direc-
ives aimed at improving vaccine efﬁcacy in infants and young
hildren: (1) increase the amount of CF antigens delivered in each
ose of vaccine; (2) include CS6 in the vaccine formulation to
mprove coverage in the ﬁeld; (3) evaluate the potential value of
dding a mucosal adjuvant to the formulation; and (4) in future
hase 3 efﬁcacy trials, the primary endpoint should be protec-
ion against severe disease and/or hospitalization associated with
accine-preventable cases. Aside from the point on efﬁcacy trialdesign, SBH has successfully addressed the other three WHO  rec-
ommendations by increasing the CF/CS antigen content per dose,
adding CS6, and adding an adjuvant (dmLT) to the formulation
[1,2,19,48]. Consequently, there is optimism among many investi-
gators in the ETEC vaccine ﬁeld that this second-generation vaccine,
ETVAX, will show even better immunogenicity, and ultimately pro-
tective efﬁcacy, among infant and young children in ETEC-endemic
areas.
The ACE527/dmLT candidate demonstrated signiﬁcant protec-
tive efﬁcacy (PE) in a Phase 2b challenge study (PE of 58.5% against
ETEC diarrhea of any severity) [33]. At the concentrations of cells
in the vaccine, it was  necessary to have the dmLT in the vaccine to
demonstrate signiﬁcant efﬁcacy. This vaccine needs further process
development work to allow for co-formulation of its three vaccine
strains plus dmLT before studies can begin at a developing-country
site.
Progress has also been made by the Center for Vaccine Devel-
opment (CVD) at the University of Maryland, Baltimore toward
achieving stable attenuated Shigella-ETEC antigen hybrids that
could become a combined vaccine, since constructs would express
both Shigella-speciﬁc LPS serotype “O” antigens as well as ETEC-
speciﬁc CF/CS antigens and LTB (constructed in GuaBA Shigella
mutants) [1,2]. In a similar vein, the biotechnology company
Prokarium has a combined ETEC-typhoid vaccine candidate in
preclinical development (Typhetec®) that utilizes an attenuated
typhoid vaccine strain to vector an LT-ST fusion protein plus a broad
array of colonization factor epitopes [43].
Other ETEC vaccine candidates based on subunits, toxins, or
novel antigens are also under development. An innovative, new
subunit ETEC candidate using ﬁmbrial tip proteins and adminis-
tered intradermally with an LT-based adjuvant (mLT) is the most
advanced subunit approach. In a recent Phase 1 study, a CfaE
(CFA/I tip adhesin) prototype induced strong immune responses
at systemic and mucosal sites [2,19,43,47]. In follow-up, the U.S.
Naval Medical Research Center (NMRC) also recently completed
a Phase 2b immunization and challenge study with a CfaE-dmLT
accine
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rototype vaccine, which also yielded encouraging results suppor-
ing the concept that, under appropriate conditions, a parenterally
dministered subunit vaccine may  prevent ETEC diarrhea. Based on
hese promising Phase 1/2b results, NMRC is working with PATH
nd other partners to accelerate the further development of this
oncept as a complete vaccine and to optimize the formulation,
ose, adjuvant(s), and route of delivery to further improve and
roaden vaccine-induced protection [49].
Using a more classic approach, Kansas State University and the
ohns Hopkins Bloomberg School of Public Health have developed
 multicomponent fusion protein that will deliver the most com-
on  CFs as well as an LT–ST hybrid toxoid [2,19,23]. This innovative
oncept is currently still in the preclinical stage of development. As
entioned earlier, substantial progress has been made recently in
he identiﬁcation and testing of mutant ST toxoids that could be
dded to cellular or subunit vaccine approaches to improve strain
overage and efﬁcacy. This work is being carried out by the EntVac
onsortium, which is comprised of investigators from University of
ergen, CVD, Tulane University, Virginia University, Kansas State
niversity, and South Dakota State University. PATH, GLOBVAC,
nd STOPENTERICS are also supporting this effort. Novel toxoids
nd the application of new “Omics” technologies and other gene-
ased approaches also offer great promise for yielding new vaccine
ntigens that may  provide broader protection against ETEC and for
acilitating combined vaccine approaches [2,19,21,35]. However,
hese approaches have also yet to move beyond preclinical animal
tudies.
. Likelihood for ﬁnancing
In 2011, PATH and BIO Ventures for Global Health (BVGH) pub-
ished an investment case for ETEC vaccine development, which
ound that recent increases in donor investment in ETEC vaccine
esearch and development as well as encouraging technological
evelopments and promising ﬁeld data on the protective efﬁcacy
f ETEC vaccine candidates in travelers may  serve to help reduce
he perceived risk associated with investment in ETEC vaccines
27]. The analysis demonstrated that ETEC vaccines represent a
odest investment opportunity for industry with an estimated
nnual revenue potential of more than US$600 million ten years
fter global launch, with the public and private sectors in emerg-
ng middle-income economies representing approximately 38%
f the anticipated revenues. This suggests a signiﬁcant potential
eturn that may  help draw the interest of more vaccine manu-
acturers in emerging economies, such as India, Brazil, and China.
he potential market would also include military and low-income
ountry components. The growing body of evidence about longer-
erm, post-infection health conditions resulting from travelers’
iarrhea as well as recent data from GEMS strengthening the asso-
iation between a high ETEC disease burden, poor physical and
ognitive development of children in endemic areas, and family-
elated health costs are also likely to help bolster these market
stimates.
Gavi, the Vaccine Alliance has indicated an interest in enteric
accines. While Gavi has shown interest in a vaccine for ETEC alone,
heir strongest preference would be for a combined vaccine that
ncludes Shigella or another pathogen. From the market assessment
entioned above, it is clear that the travel medicine industry would
lso be more enthusiastic about use of a combined ETEC-Shigella
accine than a standalone product. In addition, recent PATH efforts
o collaborate with the LiST modeling group at the Johns Hopkins
loomberg School of Public Health [19,24–26,35] and investigators
t the University of Florida on vaccine impact and cost-effectiveness
stimates have started to build an even stronger public health
ase for the development of an ETEC vaccine that could
[ 34 (2016) 2880–2886 2885
eventually be used together with vaccines against Shigella or other
enteric pathogens in a combination vaccine formulation.
Most ETEC vaccine development efforts to date have been con-
ducted by governmental agencies, academia, and the military.
However, in recent years, nonproﬁt organizations have begun to
play a more important role in moving the ﬁeld forward, which has
helped to justify further investment.
In general, ﬁnancing options for ETEC vaccines are limited but
may  be further enhanced if ETEC vaccines were part of a combined
vaccine approach [35] or if awareness of ETEC disease burden and
its impact on more long-term health and family- and national-level
economics were better appreciated [51]. Higher disease burden
estimates forthcoming from the recent GEMS re-analysis as well
as the development of better point-of-care diagnostics could help
local, regional, and global public health stakeholders gain a better
awareness of the impact of ETEC-associated illness on child health
and development.
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